Announcements Trials
Browse Landscape

Status

Unknown 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 13Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma 1

Interventions

Observation 21Blood Specimen Collection 20Drug Therapy 13Surveys and Questionnaires 8Surgical Procedures, Operative 8Immunotherapy 7Immune Checkpoint Inhibitors 7Positron Emission Tomography Computed Tomography 5Hematologic Tests 5Watchful Waiting 4Neoadjuvant Therapy 4Fluorodeoxyglucose F18 4Bevacizumab 4darolutamide 3Tyrosine Kinase Inhibitors 3Therapeutics 3Standard of Care 3Radiotherapy 3Indocyanine Green 3Imatinib Mesylate 3Endoscopic Mucosal Resection 3Docetaxel 3Cyclophosphamide 3Capecitabine 3Artificial Intelligence 3tislelizumab 2pertuzumab 2palbociclib 2obinutuzumab 2nilotinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Observational × disitamab vedotin × Clear all
NCT07490990 2026-03-24

A Real-World, Single-Arm Study Protocol of Disitamab Vedotin in Combination With Immunotherapy and Multimodal Radiation Therapy for HER2-Positive Advanced Gastric Cancer: After Second-Line Treatment Failure

West China Hospital

Not yet recruiting
30 enrolled
Gastrointestinal

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡